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Background: In South Korea, about 20 types of antiretroviral drugs are used in the treatment of patients with
human immunodeficiency virus/acquired immune deficiency syndrome. Since 2010, raltegravir, etravirine, and
darunavir have been spotlighted as new drugs for highly active antiretroviral therapy (HAART)-experienced adults
with resistant HIV-1 in South Korea. In this study, we investigated potential susceptibility of pseudoviruses derived
from treatment-experienced Korean patients to etravirine vs efavirenz and to darunavir vs amprenavir and indinavir
using a modified single-round assay.
Methods: Pseudoviruses derived from nine treatment-experienced patients infected with HIV-1 were investigated
by comparison with the wild-type strain pNL4-3. The 50% inhibitory concentration (IC50) values were calculated and
drug susceptibility was compared. The intensity of genotypic drug resistance was classified based on the ‘SIR’
interpretation of the Stanford data base.
Results: Drug susceptibility was generally higher for etravirine and darunavir compared with efavirenz, amprenavir,
and indinavir in pseudoviruses derived from treatment-experienced patients. Pseudoviruses derived from patients
KRB4025 and KRB8014, who exhibited long-term use of protease inhibitors, showed an outside of tested drug
concentration, especially for amprenavir and indinavir. However, they exhibited a lower fold-change in resistance to
darunavir.
Conclusions: Etravirine and darunavir have been used in HAART since 2010 in South Korea. Therefore, these
antiretroviral drugs together with other newly introduced antiretroviral drugs are interesting for the optimal treatment
of patients with treatment failure. This study may help to find a more effective HAART in the case of HIV-1 infected
patients that have difficulty being treated.
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More than 30 commercial antiretroviral drugs have been
used worldwide for the treatment of patients infected
with human immunodeficiency virus who show acquired
immunodeficiency syndrome (HIV/AIDS). Although
both mortality and morbidity have declined after the use
of combinations of more than 30 commercial antiretro-
viral drugs [1,2], many drug-resistant variants have been* Correspondence: juyeon.choi.hb@gmail.com
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unless otherwise stated.reported after the initiation of highly active antiretroviral
therapy (HAART). In South Korea, about 20 of the anti-
retroviral drugs approved by the United States Food and
Drug Administration (FDA) have been administered to pa-
tients with HIV/AIDS since zidovudine was first intro-
duced in 1991 [3]. HAART including protease inhibitors
has been used in the treatment of such patients since 1997
[4]. Generally, combination therapy consists in the use of
two nucleoside reverse transcriptase inhibitors (NRTIs) or
of a protease inhibitor (PI) and a non-nucleoside reverse
transcriptase inhibitor (NNRTI) concomitantly for thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have some problems that stem from their relatively low
genetic barrier to resistance, their pill burden, the cross-
resistance between them, and tolerability problems in
first-generation drugs and first-line antiretroviral therapy
[5,6]. Recently, etravirine was spotlighted as a second-
generation NNRTI that exhibits a higher genetic barrier to
resistance [7]. Etravirine was approved by the FDA in
January 2008 and is reportedly effective in treatment-
experienced patients infected with HIV/AIDS, as de-
scribed by several research groups [8,9]. Darunavir, which
was approved in June 2006, is the latest licensed protease
inhibitor with in vitro activity against both wild-type (WT)
and PI-resistant HIV-1 isolates, and ritonavir-boosted dar-
unanvir exhibits clinical efficacy in patients in whom mul-
tiple PI-containing regimens have failed [10]. It has been
suggested that darunavir has virological response that is
superior to that achieved using comparable PIs in patients
harboring PI-resistant virus [11].
Especially, etravirine and darunavir have been intro-
duced in South Korea since 2010, although other anti-
retroviral drugs of the same class have been already used
in the scope of HAART. To estimate drug susceptibility
and fold changes in the resistance to newly introduced
antiretroviral drugs, such as etravirine and darunavir,
compared with generally used antiretroviral drugs of the
same class, we investigated HIV-1 pseudoviruses derived
from treatment-experienced patients using an estab-
lished and modified phenotypic drug susceptibility assay.
We analyzed genetic variations in the HIV-1 gag-pol se-
quences to investigate actual phenotypic drug resistance
interpretation in vitro in contrast to predicted genotypic
drug resistance interpretation based on the Stanford
HIV Drug Resistance Database (Stanford DB), focusing
specifically on NNRTI- and PI-related drug resistance.
Results
The characteristics of HIV-1 derived from treatment-
experienced patients
Table 1 shows drug resistance-related mutations and
amino acid polymorphisms for pol in patients with nine
treatment experience who were infected with HIV sub-
type B. All treatment-experienced patient-derived pseu-
doviruses, with the exception of those derived from
patient KRC0064, were predicted to be resistant to more
than one NRTI, as assessed by genotyping. The analysis
of genotypic drug resistance in all patients, with the ex-
ception of patient KRC0064, suggested that it was resist-
ant to at least one class of antiretroviral drugs (Table 1).
Most of the patients were treated with HAART combin-
ing NRTI and PI or NRTI and NNRTI. The drug suscep-
tibility based on the IC50 value and fold change (FC) was
calculated relative to that of the WT (Table 1).IC50 determination for two NNRTIs and three PIs using
WT-derived pseudoviruses
The IC50 for five antiretroviral drugs was analyzed using
WT-derived pseudoviruses to establish a standard level
using XLfit (IDBS). The following antiretroviral drugs
were tested in parallel: efavirenz and etravirine, ampre-
navir, indinavir, and darunavir. Figure 1 shows a sig-
moidal dose–response curve between serially diluted
drugs and infectivity. For each antiretroviral drug, the
IC50 was as follows (in descending order for each drug
category): efavirenz (4.40E–02 nM) and etravirine
(1.34E–02 nM) among NNRTIs; and indinavir (13.5
nM), amprenavir (7.17 nM), and darunavir (6.80E–01
nM) among PIs. The FC in drug resistance was com-
pared with the IC50 value of the WT against each anti-
retroviral drug (Figure 1).
Fold resistance to etravirine and darunavir compared
with generally used drugs of the same class
Some pseudoviruses derived from treatment-experienced
patients showed a more than 100-fold higher level of
phenotypic drug resistance than did the WT, based on
FC. However, the drug susceptibility to new antiretro-
viral drugs was higher than that observed for the gener-
ally used antiretroviral drugs in these cases (Table 1 and
Figure 1). In the case of etravirine, the overall IC50
values were generally lower than those of darunavir. In
addition, most patient-derived pseudoviruses showed
higher drug susceptibility to etravirine compared with
efavirenz (Table 1 and Figure 1). Therefore, the resistance
of pseudoviruses derived from treatment-experienced
patients to etravirine was generally lower than that ob-
served for efavirenz, with the exception of those derived
from patient KRB8067. In particular, patient KRC4543,
who was infected with the 69 insertion complex in reverse
transcriptase, exhibited a 3- and 6-FC in resistance to efa-
virenz (0.139 nM) and etravirine (0.0773 nM) compared
with WT, respectively.
The treatment-experienced patients who received a
PI-containing regimen over 6 years (KRB8014 and
KRB4025) showed the highest level of FC in the resist-
ance to amprenavir, indinavir, and darunavir. Pseudo-
viruses derived from patients KRB8014 and KRB4025
showed a more than 200-FC in the resistance to daruna-
vir. Conversely, the IC50 value against APV and IDV was
not calculated in these patients because the pseudo-
viruses derived from them had a level of phenotypic
drug resistance that was too high (Table 1 and Figure 1).
Comparison of the results of phenotypic and genotypic
drug resistance assays
Generally, there was some discordance between genotypic
and phenotypic drug resistance in this study. Phenotypic
drug susceptibility according to FC was generally higher






Sample date (PR/RT) APV IDV DRV EFV ETR
HIV-1 pNL4-3 Wild type (None/None/None) B/B Genotypea
(Mutation Score)
S (0) S (0) S (0) S (0) S (0)
Phenotypeb
(IC50, FC*)
7.17 nM, 1 13.5 nM, 1 6.80E–01 nM, 1 4.40E–02 nM, 1 1.34E–02 nM, 1
KRB8067 Treatment-experienced patient infected with HIV. Treatment
with AZT, 3TC, and IDV from Jul. 2003 to Apr. 2006
B/B Genotype
(Mutation Score)
R (60) R (80) S (0) S (0) S (0)
(M46I,I54V,V82A,L10F/M184V/None) Apr. 24, 2006 Phenotype
(IC50, FC)
3.52 nM, 0.5 34.4 nM, 2.6 8.58E–02 nM, 0.1 5.00E–02 nM, 1.1 7.99E–02 nM, 6.0
KRC2065 Treatment-experienced patient infected with HIV. Treatment
with AZT, 3TC, and IDV from May 2002 to Oct. 2004.
B/B Genotype
(Mutation Score)
S (0) S (0) S (0) S (0) S (0)
(L10V/M41L,M184V/None) Oct. 14, 2004 Phenotype
(IC50, FC)
171 nM, 23.9 91.7 nM, 6.8 43.8 nM, 64.4 5.47 nM, 124.3 3.84E–01 nM, 28.7
KRB5018 Treatment-experienced patient infected with HIV. Treatment
with AZT, ddI, 3TC, IDV, and EFV from Jul. 1998 to Dec. 2004.
B/B Genotype
(Mutation Score)





44.2 nM, 6.2 4.83 nM, 0.4 2.53E–01 nM, 0.4 119 nM, 2704.6 9.20E–01 nM, 68.7
KRC2092 Treatment-experienced patient infected with HIV. Treatment
with AZT, 3TC, IDV, and EFV from Jan. 2003 to Nov. 2004.
B/B Genotype
(Mutation Score)





81.9 nM, 11.4 53.4 nM, 4.0 1.45 nM, 2.1 10.5 nM, 238.6 5.00E–02 nM, 3.7
KRB4025 Treatment-experienced patient infected with HIV. Treatment
with AZT, LPV/RTV, ddI, and 3TC from May 2003 to Feb. 2009.
B/B Genotype
(Mutation Score)





<1e–004 nM, >>> >1000 nM, >> 164 nM, 241.2 7.51 nM, 170.7 5.77 nM, 430.6
KRB8014 Treatment-experienced patient infected with HIV. Treatment




R (140) R (150) I (20) R (90) I (15)
(M46L,I54V,L76V,V82A,L90M,L10V,K43T,A71V/M41L,L74V,M184V,
L210W,T215C,K219E/L100I,K103N) Mar. 5, 2009
Phenotype
(IC50, FC)
<1e–004 nM, >>> >1000 nM, >> 162 nM, 238.2 6.34E–02 nM, 1.4 6.03E–02 nM, 4.5
KRC3221 Treatment-experienced patient infected with HIV. B/B Genotype
(Mutation Score)
S (10) I (30) S (0) I (15) S (0)
(V82A,L10I/L210W,T215Y/K103T) Nov. 1, 2008 Phenotype
(IC50, FC)
141 nM, 19.7 324 nM, 24.0 1.70 nM, 2.5 8.41E–01 nM, 19.1 3.04E–02 nM, 2.3
KRC0064 Treatment-experienced patient infected with HIV. Treatment
with AZT, 3TC, and LPV/RTV from Feb. 2009 to Oct. 2009.
B/B Genotype
(Mutation Score)
S (0) S (0) S (0) S (0) S (0)
(None/None/None) Oct. 22, 2009 Phenotype
(IC50, FC)
1.69 nM, 0.2 8.98E–01 nM, 0.1 5.87E–02 nM, 0.1 4.10E–01 nM,9.3 8.83E–02 nM,6.6










Table 1 Comparison of drug resistance level between genotype and phenotype, focusing on the HIV-1 gag-pol region (Continued)
Treatment-experienced patient infected with HIV. Treatment





21.5 nM, 3.0 129 nM, 9.6 2.26 nM, 3.3 1.39E–01 nM, 3.2 7.73E–02 nM, 5.8
Jan. 8, 2009
aGenotype means predicted genotypic drug resistance against antiretroviral drugs based on the Stanford DB. The Mutation Score is provided as the sum of the scores of each drug-resistance-related mutation site.
Key: S, susceptible (susceptible, potential low-level resistance); I, intermediate (low-level, intermediate-level resistance); R, resistant (high-level resistance).
(ARV Resistance Estimates based on the Stanford DB were evaluated as overall scores of fold increase in resistance as ‘Susceptible’ (0–14), ‘Intermediate’ (15–59), and ‘Resistant’ (>60) compared with the WT-derived
pseudovirus as a standard).
PR means protease and RT means reverse transcriptase.
Three protease inhibitors (PIs): indinavir sulfate (IDV, Merck & Co., Inc., Whitehouse Station, NJ, USA), amprenavir (APV, GlaxoSmithKline (GSK)), and darunavir (DRV, Tibotec).
Two non-nucleoside reverse transcriptase inhibitors (NNRTIs): efavirenz (EFV, Merck) and etravirine (ETR, Tibotec).
§All patient-related data were anonymized before analysis and all indications were converted into designated labels at the Korea Centers for Disease Control & Prevention (KCDC).
bPhenotype means phenotypic drug susceptibility based on 50% inhibitory concentration and calculated fold change.
*FC (fold change) in ‘Phenotype’ means fold resistance values compared with the WT pseudovirus based on data obtained using a modified phenotypic drug susceptibility assay. The drug resistance index calculated










Figure 1 Comparison of IC50 against three PIs (amprenavir, indinavir, and darunavir) and two NNRTIs (etravirine and efavirenz) for nine
treatment-experienced patient-derived recombinant pseudoviruses based on simultaneous measurement of drug susceptibility. Each
color indicates the following antiretroviral drugs: blue (amprenavir), green (indinavir), brown (darunavir), gray (efavirenz), and orange (etravirine).
Each experiment was repeated three times. (a) pNL4-3, WT; (b) KRB8067; (c) KRC2065; (d) KRB5018; (e) KRC2092; (f) KRB4025; (g) KRB8014;
(h) KRC3221; (i) KRC0064; (j) KRC4543.
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amprenavir, and indinavir for each pseudovirus derived
from treatment-experienced patients infected with HIV-1
(Table 1 and Figure 1). Darunavir-related resistance
showed the most similar pattern between genotype and
phenotype. Other antiretroviral drugs, such as amprenavir,
indinavir, efavirenz, and etravirine, exhibited somewhat
different patterns between genotype and phenotype.
In the case of amprenavir and indinavir in patient
KRB8067, the phenotypic drug susceptibility was a little
higher and similar to that of the WT, compared with the
predicted genotypic drug resistance, with a mutation
score of 60 and 80, respectively (Table 1).
In patients KRB8014 and KRC4543, the genotypic
drug resistance-related NNRTIs suggested that they were
‘resistant’ for efavirenz and an ‘intermediate’ status for
etravirine, whereas the phenotypic drug susceptibility
was similar to that of the WT and less than 6 FC. In the
case of patient KRB5018, both results show similar pat-
tern that efavirenz and etravirine related genotypic drug
resistance was predicted to be ‘resistant’ (mutation score
90), ‘intermediate’ (mutation score 15), and phenotypic
drug resistance was also 2704.6 FC, 68.7 FC, respect-
ively. The etravirine-related FC was highest in patient
KRB4025 (430.6 FC) (Table 1).
In patient KRC0064, drug resistance was predicted to
be susceptible for all antiretroviral drugs by genotyping,
although this patient had been receiving a regimen of zi-
dovudine, lamivudine, and lopinavir/ritonavir for more
than 8 months. The drug susceptibility for PIs was
higher than that of the WT, and that of NNRTIs was a
little higher than that of the WT. These predicted results
were similar between genotypic and phenotypic drug
resistance.
KRC4543, a patient who was infected with the 69 in-
sertion complex in reverse transcriptase, exhibited a
lower phenotypic drug resistance compared with the
predicted genotypic drug resistance. The genotypic drug
resistance was suggested that they were ‘intermediate’
(mutation score of 20), whereas the phenotypic drug
susceptibility in resistance to amprenavir was lower (3.0
FC). Moreover, values of 9.6 FC for indinavir and 3.3 FC
for darunavir were observed in patient KRC4543. In con-
trast, phenotypic drug susceptibility was higher for both
etravirine (5.8 FC) and efavirenz (3.2 FC), whereas geno-
typic drug resistance was predicted as being ‘inter-
mediate’ (mutation score of 30 because of the K101P
and K103N mutations) and ‘resistant’ (mutation score
of 90 because of the K101P and K103N mutations),
respectively.
Discussion
The genotypic drug resistance, HIV viral load and CD4
T cell counts are generally used to providing additionalinformation to permit optimal treatments for patients
with HIV/AIDS. Apart from drug resistance, there are
limits to interpretation using such tests in terms of drug
adherence and medical opinion, especially in cases of
treatment failure or discordant patients with HIV/AIDS.
This study was designed to compare and estimate
genotypic drug resistance and phenotypic drug suscepti-
bility focusing on newly introduced antiretroviral drugs
such as darunavir and etravirine. And, we assume that
antiretroviral drugs such as darunavir and etravirine
have the potential to be more efficacious in HAART-
experienced patients after their introduction in 2010 in
South Korea. Prior to the introduction of darunavir and
etravirine, tested samples were selected and analyzed.
Etravirine was the first NNRTI to show antiviral activ-
ity in treatment-experienced adult patients with HIV-1
strains that were resistant to NNRTIs and other anti-
retroviral agents [12]. Etravirine has been reported as
being efficacious in achieving viral suppression and im-
proving immune function in treatment-experienced
HIV-infected patients since it was approved twice-daily
darunavir coadministered with ritonavir for use by
treatment-experienced adults in June 2006 [8,9,13]. Etra-
virine is also an approved NNRTI that can overcome
single point mutations, such as K103N, that confer
cross-resistance to both nevirapine and efavirenz [7]. In
general, the high genetic barrier of etravirine requires
the accumulation of more than three resistance-
associated mutations to achieve diminished drug effi-
cacy, and the relative roles of each of these mutations in
the development of such resistance are unclear [8]. Dar-
unavir has also been reported as a second-generation PI
that has a virological response that is superior to that
achieved by comparable PIs in patients harboring PI-
resistant viruses [11,14]. Darunavir is an HIV-1 PI with a
broad-spectrum in vitro amprenavir activity in both
wild-type viruses and multidrug-resistant HIV-1 strains
[15]. Darunavir with low-dose ritonavir has demon-
strated anti-retroviral efficacy and tolerability in clinical
trials in a range of HIV-1-infected patients, and is ap-
proved for use in treatment-naïve and treatment-
experienced patients in several countries [15]. Moreover,
in patients with resistant viruses and few remaining
treatment options, the combination of raltegravir, etra-
virine, and darunavir with low-dose ritonavir resulted in
excellent virological outcomes in the AIDS and viral
hepatitis (ANRS) 139 TRIO trial [16].
Etravirine-related resistance mutation sites were re-
ported to exhibit more complex combinations than do
other NNRTIs, such as nevirapine and efavirenz [6].
Etravirine-related resistance mutations are different from
those of other same class of drugs (V90I, A98G, L100I,
K101E/H/P, V106I, E138A/G/K, V179D/F/T, Y181C/I/V,
G190S/A, and M230L), although only one or two
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level resistance in other first-generation NNRTIs [6,14].
In our study, patients KRC2092 and KRC5018 had
values of 238.6 FC and 2704.6 FC for efavirenz, in con-
trast with 3.7 FC and 68.7 FC for etravirine compared
with the WT. This suggests that etravirien is more ef-
fective than efavirenz in these treatment-experienced pa-
tients. However, the predicted genotypic drug resistance
was similar, with an intermediate status (mutation score
of 30 because of the Y181C mutation), whereas the
phenotypic drug susceptibility was predicted to be a little
higher for efavirenz than for etravirine in patient
KRB4025-derived pseudoviruses: 170.7 FC for efavirenz
and 430.6 FC for etravirine. Xu et al. reported that the
addition of E138K to Y181C also decreased the level of
resistance to etravirine compared with that observed for
Y181C [17]. However, Y181C was reported in only one
case (KRB4025), and no patient in our study group car-
ried the E138K mutation.
In fact, the results of the phenotypic assay may provide
incomplete information, such as FC in IC50. Neverthe-
less, the phenotypic assay can be helpful in promoting
better medical treatment by providing information such
as the interpretation of mutual connections and cross-
resistance among drug-resistant HIV variants. Therefore,
the application and accumulation of data from pheno-
typic drug susceptibility assays have the potential of pro-
viding helpful information for predicting drug resistance.Conclusion
The application of this modified phenotypic drug sus-
ceptibility study is expected to help predict drug resist-
ance as a guideline for clinicians to obtain a combined
interpretation among genotypic resistance, phenotypic
susceptibility, and effective clinical treatments before the
introduction of modified HAART regimens. Therefore,
we continuously need to predict the effectiveness of do-
mestic newly introduced antiretroviral drugs in a large
antiretroviral drug-based HAART-experienced patient
groups.Methods
Amplification and Insertion of patient-derived HIV-1
gag-pol gene into pNL4-3-ΔE-GFP
Purified gag-pol PCR products derived from patients
were cloned into pNL4-3-ΔE-GFP (green fluorescent
protein) by ligation to the Apa I/Age I fragment of
pNL4-3-ΔE-GFP (NIH AIDS Research & Reference Re-
agent Program) [18]. Selected positive clones were kept
at −80°C in 20%–25% glycerol stocks. Positive-clone-
derived DNA was prepared using HiSpeed Plasmid Midi
Kits (Qiagen, Hilden, Germany).Transfection, pseudovirus production, and quantification
of infectivity
The transfection and infection processes were modified
from methods described previously [19]. 293 T cells were
cotransfected with wild-type (WT, pNL4-3-ΔE-GFP) or
recombinant pNL4-3-ΔE-GFP and pVSV-G using Lipo-
fectamine 2000 (Invitrogen). The pseudoviruses were ob-
tained at 48 h posttransfection and filtered using
Steriflip filters (Millipore. Madison, WI, USA).
Phenotypic drug susceptibility assay
For measuring phenotypic drug susceptibility against
antiretroviral drugs, we used five antiretroviral drugs.
Each PI was used at a concentration that ranged from
1000 to 10−3 nM 4 h after transfection using 24-well
plates. Viral infectious units were determined by count-
ing the number of β-Gal + cell colonies using 10-fold di-
lutions that gave between 150 and 200 cell colonies.
Each NNRTI (1000 to 10−5 nM) was added to the TZM-
bL cell line at the start of infection. The β-galactosidase
activity was measured by X-gal staining on day 2 after
infection. Three tests for each drug concentration were
executed, and relative infectivity was calculated by direct
counting of blue foci. The 50% inhibitory concentration
(IC50) values were calculated by curve fitting of XLfit4.2
(IDBS, Guildford, Surrey, UK). Fold changes in resist-
ance values were compared with the WT-derived pseu-
dovirus based on data obtained using a modified
phenotypic drug susceptibility (In-house Phenotype) and
the genotypic drug resistance (Stanford DB) (Table 1).
Prediction of drug resistance level using genotypic
resistance assay
The conditions of reverse transcription polymerase
chain reaction (RT–PCR) and PCR were as described
previously [19]. The PCR product of gag-pol (about
1.5 kb) was used for ligation after purification using
NucleoFast® 96 PCR (MACHEREY-NAGEL GmbH &
Co.KG). The PCR product of pol gene sequences was
subjected to direct sequencing in an ABI Prism Dye Ter-
minator Cycle Sequencing Ready Reaction Kit (PerkinEl-
mer, Waltham, MA, USA) in an automated sequencer
(ABI Prism 3110 DNA sequencer, Applied Biosystems,
Foster City, CA, USA). The pol nucleotides and encoded
amino acid sequences were aligned using EditSeq and
MegAlign programs in the Lasergene software package
(version 5.06; DNASTAR Inc., Madison, WI, USA). The
interpretation of the resistant mutations was based on
the Stanford DB (Drug Resistance Algorithm, Beta Test
(version 6.3)), release notes for HIV seq, HIV db, HIV alg.
http://sierra2.stanford.edu/sierra/servlet/JSierra?action=
sequenceInput).
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